{
    "nct_id": "NCT03673943",
    "official_title": "An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)",
    "inclusion_criteria": "* Confirmed or suspicion of NET based on histology/ biopsy report.\n* Confirmed or suspicion of NET based on conventional imaging scans of affected area such as MRI and/or contrast enhanced CT and/or an FDG PET\n* CT scan and/or NaF PET-CT scan and/or OctreoScan® performed within 8 weeks prior to study date.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant, planning to be pregnant within the next two weeks\n* Inability to provide written consent.\n* Therapeutic use of any somatostatin analogue, including Sandostatin® long-acting and Lanreotide (within 28 days) and Sandostatin® (within 2 days) prior to study imaging. If a subject is on Sandostatin® long-acting or Lanreotide, a wash-out period of 28 days is required before the injection of the study drug.",
    "miscellaneous_criteria": ""
}